RxDoctor Payments Data

Ronald Polinsky, MD

Cardiovascular Disease · Wyomissing, PANPI 1235188319

Payments from drug & device makers

$210,064in general payments, 2019–2025

Across 253 payments — averaging $830.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GE HealthCare$134K
  • Amarin Pharma, Inc.$56K
  • Janssen Research & Development, LLC$18K
  • Amgen$433
  • Johnson & Johnson$429
  • Pfizer$297
  • plus $757 from 13 others

What the payments were for

  • Speaking & faculty fees$49,50086%
  • Travel & lodging$2,6685%
  • Food & beverage$5,58610%
  • Education$260%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$210,064 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$245,820
Medicare patients
1,515
Services billed
4,564

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban509$589,756
XareltoRivaroxaban219$259,685
EntrestoSacubitril/Valsartan121$155,362
VascepaIcosapent Ethyl44$34,118
FarxigaDapagliflozin Propanediol35$29,520
BrilintaTicagrelor26$23,828
JardianceEmpagliflozin14$22,580
Bisoprolol Fumarate527$16,669
Icosapent Ethyl31$11,652
Praluent PenAlirocumab13$10,393
Repatha SureclickEvolocumab12$10,327
Metoprolol Succinate567$9,422
Ranolazine ErRanolazine91$8,117
Atorvastatin Calcium771$7,503
Valsartan133$5,759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$297$589,756509 claims
Johnson & JohnsonXarelto$429$259,685219 claims
NovartisEntresto$97$155,362121 claims
AstraZenecaFarxiga, Brilinta$145$53,34861 claims
Boehringer IngelheimJardiance$14$22,58014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Wyomissing

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →